Responses were similar among patients with estrogen patches and ARPIs compared to luteinizing hormone releasing hormone ...
Barry Goy, MD, provides insight into the clinical implications of a retrospective analysis examining 15-year outcomes in patients with intermediate-risk prostate cancer.
Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...
Cade, Telix Group Chief Medical Officer, said, “Telix will feature in four presentations at this year’s ASCO GU, which showcase the depth and differentiation of our therapeutic urologic pipeline, ...